- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01484145
Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
October 18, 2012 updated by: Nitric BioTherapeutics, Inc
An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail
The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel.
Iontophoretic delivery involves the use of a small electric charge to deliver drug across skin and nails.
Study Overview
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Cetero Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Positive KOH
- 25-75% involvement of the visible nail.
- Nail plate must be < 3 mm thick.
- Must have signed informed consent.
- Must agree to avoid any type of pedicure or application of any nail polish product or nail cosmetic to the toenails after the screening visit until Day 28.
- Female subjects of childbearing potential must agree to take measures to avoid pregnancy until the day after Day 28
- Must agree to avoid the use of oral antifungals or topical terbinafine anywhere on the body until the day after Day 28. Topical antifungals other than terbinafine can be used on the body other than the feet after Day 0.
Exclusion Criteria:
- Presence of proximal subungual onychomycosis or white superficial onychomycosis
- Fungal involvement of a majority of the lunula
- Subjects with psoriasis, eczema, or other abnormalities that could result in a clinically abnormal nail
- Presence of dermatophytoma or onychomycotic spikes or exclusively lateral groove involvement
- Traumatized or dystrophic target great toenail.
- Known diabetics
- Subjects with peripheral vascular disease
- Subjects who are immunosuppressed (chronic corticosteroid therapy, solid organ or bone marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or planned within the next 12 months), or HIV infection.
- Use of systemic corticosteroids within 30 days preceding Day 0
- Use of topical antifungals on the feet in the preceding 30 days of Day 0 through Day 28
- Use of topical terbinafine in the 30 days prior to treatment through Day 28
- Use of systemic antifungals in the preceding 120 days of Day 0 through Day 28
- Use of any investigational drug(s) within 30 days (120 days for systemic antifungals) preceding Day 0 through Day 28
- Has previously participated in this study
- Is pregnant or is a nursing mother
- Women of of child bearing potential who are not using an adequate form of contraception (or abstinence)
- Subjects with pacemakers/automatic implantable cardioverter/defibrillators
- Subjects with an implantable electronic device.
- Subjects with a bleeding disorder or who are using warfarin or any other blood coagulation modulator including aspirin in the 14 days prior to treatment through Day 28
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 6 mA.min, 20 mins
|
4% w/w terbinafine HCL gel, single dose,
|
EXPERIMENTAL: 6 mA/min, 20 mins, clamping
|
4% w/w terbinafine HCL gel, single dose,
|
EXPERIMENTAL: 6 mA/min, 20 mins, debridement, clamping
|
4% w/w terbinafine HCL gel, single dose,
|
EXPERIMENTAL: 15 mA/min, 30 mins, clamping
|
4% w/w terbinafine HCL gel, single dose,
|
EXPERIMENTAL: 15 mA/min, 50 mins, debridement, clamping
|
4% w/w terbinafine HCL gel, single dose,
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Level of terbinafine in the nail bed (ng/mg)
Time Frame: Day 28
|
Day 28
|
Plasma terbinafine levels (ng/ml)
Time Frame: Day 28
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of treatment emergent adverse events (AEs)& Serious Adverse Events (SAEs)
Time Frame: 60 days
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (ACTUAL)
March 1, 2012
Study Completion (ACTUAL)
April 1, 2012
Study Registration Dates
First Submitted
November 28, 2011
First Submitted That Met QC Criteria
November 30, 2011
First Posted (ESTIMATE)
December 2, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
October 19, 2012
Last Update Submitted That Met QC Criteria
October 18, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTP-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Mahidol UniversityCompletedNon-dermatophyte OnychomycosisThailand
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisUnited States, Canada
-
PfizerCompletedOnychomycosis of ToenailsUnited States, Canada
Clinical Trials on Terbinafine HCl
-
Novartis PharmaceuticalsCompleted
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
Transport PharmaceuticalsCompleted
-
NovartisCompleted
-
MediQuest TherapeuticsCompleted
-
NovartisCompletedHIV Infections | Candidiasis, OralUnited States
-
Nitric BioTherapeutics, IncCompletedOnychomycosisUnited States, Canada
-
BCDiabetes.CaBritaMed, Inc.Unknown
-
Hallux, Inc.Active, not recruitingOnychomycosis of ToenailUnited States